General Information of Drug Therapeutic Target (DTT) (ID: TTIKWV4)

DTT Name Geranyltranstransferase (FDPS)
Synonyms
KIAA1293; Geranylgeranyl pyrophosphate synthase; Geranylgeranyl diphosphate synthase; GGPS1; GGPPSase; GGPP synthase; Farnesyltranstransferase; Farnesyl pyrophosphate synthase; Farnesyl diphosphate synthase; FPS protein; FPP synthase; Dimethylallyltranstransferase; (2E,6E)-farnesyl diphosphate synthase
Gene Name FDPS
DTT Type
Successful target
[1]
BioChemical Class
Alkyl aryl transferase
UniProt ID
FPPS_HUMAN
TTD ID
T86528
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
EC Number
EC 2.5.1.10
Sequence
MPLSRWLRSVGVFLLPAPYWAPRERWLGSLRRPSLVHGYPVLAWHSARCWCQAWTEEPRA
LCSSLRMNGDQNSDVYAQEKQDFVQHFSQIVRVLTEDEMGHPEIGDAIARLKEVLEYNAI
GGKYNRGLTVVVAFRELVEPRKQDADSLQRAWTVGWCVELLQAFFLVADDIMDSSLTRRG
QICWYQKPGVGLDAINDANLLEACIYRLLKLYCREQPYYLNLIELFLQSSYQTEIGQTLD
LLTAPQGNVDLVRFTEKRYKSIVKYKTAFYSFYLPIAAAMYMAGIDGEKEHANAKKILLE
MGEFFQIQDDYLDLFGDPSVTGKIGTDIQDNKCSWLVVQCLQRATPEQYQILKENYGQKE
AEKVARVKALYEELDLPAVFLQYEEDSYSHIMALIEQYAAPLPPAVFLGLARKIYKRRK
Function
FPP also serves as substrate for protein farnesylation and geranylgeranylation. Catalyzes the sequential condensation of isopentenyl pyrophosphate with the allylic pyrophosphates, dimethylallyl pyrophosphate, and then with the resultant geranylpyrophosphate to the ultimate product farnesyl pyrophosphate. Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones.
KEGG Pathway
Terpenoid backbone biosynthesis (hsa00900 )
Metabolic pathways (hsa01100 )
Biosynthesis of antibiotics (hsa01130 )
Reactome Pathway
Activation of gene expression by SREBF (SREBP) (R-HSA-2426168 )
Cholesterol biosynthesis (R-HSA-191273 )
BioCyc Pathway
MetaCyc:ENSG00000160752-MON

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
8 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Alendronate DMY2KX9 Bone Paget disease Approved [2]
Ibandronate DM0QZBN Hypercalcaemia 5B91.0 Approved [2]
Incadronate DM3DSVJ Hypercalcaemia 5B91.0 Approved [3]
Minodronate DM50PMY Osteoporosis FB83.0 Approved [4]
NERIDRONIC ACID DMMPG5V Bone disease FC0Z Approved [5]
Pamidronate DMB4AVP Bone Paget disease Approved [6]
Risedronate DM5FLTY Bone Paget disease Approved [7]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Approved Drug(s)
1 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zarnestra DMF30HL Acute myeloid leukaemia 2A60 Phase 3 [8]
------------------------------------------------------------------------------------
57 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
(1-hydroxy-1-phosphono-heptyl)-phosphonic acid DM5L8WX Discovery agent N.A. Investigative [9]
(2E, 6E)-farnesylbisphosphonate DM3ST2Y Discovery agent N.A. Investigative [10]
(biphenyl-3-ylamino)methylenediphosphonic acid DMGB97I Discovery agent N.A. Investigative [11]
1-(but-2-ylamino)ethyl 1,I-bisphosphonic acid DMTMZAJ Discovery agent N.A. Investigative [9]
1-[(cyclohexylamino)ethyl]-1,1-bisphosphonicacid DM1JQPW Discovery agent N.A. Investigative [9]
1-[(n-but-1-ylamino)ethyl]-1,1-bisphosphonic acid DM8VNYA Discovery agent N.A. Investigative [9]
1-[(n-hex-1-ylamino)ethyl]-1,1-bisphosphonic acid DM4ABTN Discovery agent N.A. Investigative [9]
1-[(n-oct-1-ylamino)ethyl]-1,1-bisphosphonic acid DM9ZK0D Discovery agent N.A. Investigative [9]
1-[(prop-1-ylamino)ethyl]-1,1-bisphosphonic acid DMCRHVI Discovery agent N.A. Investigative [9]
1-[(prop-2-ylamino)ethyl]-1,1-bisphosphonicacid DMSCN8J Discovery agent N.A. Investigative [9]
1-[(tert-butylamino)ethyl]-1,1-bisphosphonicacid DMLDY3H Discovery agent N.A. Investigative [9]
3-azageranylgeranyl diphosphate DM6KNMB Discovery agent N.A. Investigative [12]
BPH-252 DMUOS3G Discovery agent N.A. Investigative [1]
BPH-608 DM0NQLI Discovery agent N.A. Investigative [13]
BPH-628 DM0TJ6R Discovery agent N.A. Investigative [1]
BPH-629 DM49BFM Discovery agent N.A. Investigative [13]
BPH-675 DM3IPYV Discovery agent N.A. Investigative [13]
BPH-676 DMPKAEW Discovery agent N.A. Investigative [13]
BPH-715 DMTHW3F Discovery agent N.A. Investigative [1]
BPH-742 DMD0XEO Discovery agent N.A. Investigative [1]
CT-10 DMIVNMJ Solid tumour/cancer 2A00-2F9Z Investigative [14]
digeranyl bisphosphonate DMXK8BH Discovery agent N.A. Investigative [1]
Dimethylallyl Diphosphate DMP5I47 Discovery agent N.A. Investigative [15]
diphosphoric acid DMYWL89 Discovery agent N.A. Investigative [5]
Geranyl Diphosphate DMB9LE1 Discovery agent N.A. Investigative [16]
GERANYLGERANYL DIPHOSPHATE DMJZ0AM Discovery agent N.A. Investigative [15]
Homorisedronate DMX8DC2 Discovery agent N.A. Investigative [17]
ISOPENTENYL PYROPHOSPHATE DMTU05Y Discovery agent N.A. Investigative [15]
Isopentyl Pyrophosphate DM9J5IS Discovery agent N.A. Investigative [16]
NE-10575 DMGSNU4 Discovery agent N.A. Investigative [5]
NE10790 DMVESO2 Discovery agent N.A. Investigative [5]
NE11808 DMR92HV Discovery agent N.A. Investigative [5]
NE21650 DM58O3I Discovery agent N.A. Investigative [18]
NE58018 DM28ZPT Discovery agent N.A. Investigative [5]
NE58027 DMU4I8R Discovery agent N.A. Investigative [5]
NE58043 DMS7UNR Discovery agent N.A. Investigative [5]
NE58062 DMHIM6N Discovery agent N.A. Investigative [5]
NE97220 DMDWESP Discovery agent N.A. Investigative [5]
OLPADRONIC ACID SODIUM SALT DM1XJBE Bone resorption FC0Z Investigative [19]
PG-1014491 DMH4AKG Bone disease FC0Z Investigative [14]
Piridronic acid DMRDF8Z Discovery agent N.A. Investigative [5]
PMID12014956C12 DMFO7UC Discovery agent N.A. Investigative [12]
PMID17963374C31 DMTP5OY Discovery agent N.A. Investigative [20]
PMID17975902C5e DMS1QM8 Discovery agent N.A. Investigative [21]
PMID18295483C2 DM3GYNM Discovery agent N.A. Investigative [22]
PMID18800762C11 DM4UWKR Discovery agent N.A. Investigative [1]
PMID18800762C14 DM5T2FR Discovery agent N.A. Investigative [1]
PMID18800762C16 DM70SEQ Discovery agent N.A. Investigative [1]
PMID18800762C19 DM1QXFI Discovery agent N.A. Investigative [1]
PMID18800762C47 DMZDC14 Discovery agent N.A. Investigative [1]
PMID18800762C51 DMWFGY4 Discovery agent N.A. Investigative [1]
[2-(6-Chloro-purin-9-yl)ethyl]-bisphosphonic acid DM5LVIR Discovery agent N.A. Investigative [23]
[2-(Benzoimidazol-1-yl)ethyl]-bisphosphonic acid DM98MXT Discovery agent N.A. Investigative [23]
[2-(Imidazol-1-yl)ethyl]-bisphosphonic acid DMQZUD9 Discovery agent N.A. Investigative [23]
[2-(Imidazol-2-yl-thio)ethyl]-bisphosphonic acid DMBVDY5 Discovery agent N.A. Investigative [23]
[2-(Purin-9-yl)ethyl]-bisphosphonic acid DM3VT8M Discovery agent N.A. Investigative [23]
[2-(Pyrazol-1-yl)ethyl]-bisphosphonic acid DMJN8XK Discovery agent N.A. Investigative [23]
------------------------------------------------------------------------------------
⏷ Show the Full List of 57 Investigative Drug(s)

Molecular Expression Atlas (MEA) of This DTT

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DTT
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Osteoporosis FA20 Bone marrow 7.06E-03 -0.73 -2.57
------------------------------------------------------------------------------------

References

1 Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem. 2008 Sep 25;51(18):5594-607.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42.
4 Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid. J Med Chem. 2010 May 13;53(9):3454-64.
5 Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95.
6 Detection of nonsterol isoprenoids by HPLC-MS/MS. Anal Biochem. 2008 Dec 1;383(1):18-24.
7 Activity of bisphosphonates against Trypanosoma brucei rhodesiense. J Med Chem. 2002 Jul 4;45(14):2904-14.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl... Bioorg Med Chem. 2008 Mar 15;16(6):3283-90.
10 Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors. Bioorg Med Chem. 2008 Jan 1;16(1):390-9.
11 Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3'-azido, 3'-deoxythymidine: a QSAR i... Bioorg Med Chem. 2008 Oct 1;16(19):8959-67.
12 Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents. J Med Chem. 2002 May 23;45(11):2185-96.
13 Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10022-7.
14 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 643).
15 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
16 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
17 Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. J Biol Chem. 2001 Sep 7;276(36):33930-7.
18 Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase. Biochem Biophys Res Commun. 2002 Jan 18;290(2):869-73.
19 Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun. 1999 Feb 16;255(2):491-4.
20 Activity of sulfonium bisphosphonates on tumor cell lines. J Med Chem. 2007 Nov 29;50(24):6067-79.
21 Synthesis and biological evaluation of alpha-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate. J Med Chem. 2007 Nov 29;50(24):5967-75.
22 Design and structure-activity relationships of potent and selective inhibitors of undecaprenyl pyrophosphate synthase (UPPS): tetramic, tetronic acids and dihydropyridin-2-ones. Bioorg Med Chem Lett.2008 Mar 15;18(6):1840-4.
23 Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocy... J Med Chem. 2008 Nov 13;51(21):6800-7.